APOLLO-B Trial of Onpattro Fully Enrolls Patients with Heart Disease

APOLLO-B Trial of Onpattro Fully Enrolls Patients with Heart Disease

296019

APOLLO-B Trial of Onpattro Fully Enrolls Patients with Heart Disease

Enrollment is now completed in the Phase 3 APOLLO-B trial, which is assessing the safety and efficacy of Onpattro (patisiran) to treat heart disease in people with transthyretin-mediated (ATTR) amyloidosis, a group of conditions that includes familial amyloid polyneuropathy (FAP). The study (NCT03997383) has enrolled more than 300 participants across 90 sites in more than 20 countries, according to Alnylam Pharmaceuticals, the therapy’s developer and trial sponsor. “Today’s milestone marks an important step forward as…

You must be logged in to read/download the full post.